Drug Database · Clinicians

Oxacillin

Brands (21) Peoxa, Amboxil, Bactiox…Show all

Antibacterial (penicillin); Antibacterial (beta-lactamase resistant penicillin) PH FDA category

Rx · Prescription drug27 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 4972ec74-1d9a-de9b-e063-6394a90af786, version date December 31, 2025 (oxacillin · Onesource Specialty Pharma Limited). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE Oxacillin is indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Oxacillin is indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (See CLINICAL PHARMACOLOGY – Susceptibility Test Methods).

Oxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. Oxacillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant Staphylococcus, therapy should not be continued with oxacillin.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Oxacillin for Injection, USP and other antibacterial drugs, Oxacillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.

In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Contraindications

CONTRAINDICATIONS A history of a hypersensitivity (anaphylactic) reaction to any penicillin is a contraindication.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Bacteriologic studies to determine the causative organisms and their susceptibility to oxacillin should always be performed. Duration of therapy varies with the type of severity of infection as well as the overall condition of the patient; therefore, it should be determined by the clinical and bacteriological response of the patient.

In severe staphylococcal infections, therapy with oxacillin should be continued for at least 14 days. Therapy should be continued for at least 48 hours after the patient has become afebrile, asymptomatic, and cultures are negative. Treatment of endocarditis and osteomyelitis may require a longer duration of therapy. With intravenous administration, particularly in elderly patients, care should be taken because of the possibility of thrombophlebitis.

RECOMMENDED DOSAGES FOR OXACILLIN FOR INJECTION, USP Drug Adults Infants and Children < 40 kg (88 lbs) Other Recommendations Oxacillin 250 to 500 mg IM or IV every 4 to 6 hours (mild to moderate infections) 50 mg/kg/day IM or IV in equally divided doses every 6 hours (mild to moderate infections) 1 gram IM or IV every 4 to 6 hours (severe infections) 100 mg/kg/day IM or IV in equally divided doses every 4 to 6 hours (severe infections) Premature and Neonates 25 mg/kg/day IM or IV Directions for use For Intramuscular Use: Use Sterile Water for Injection, USP. Add 5.7 mL to the 1 gram vial and 11.5 mL to the 2 gram vial.

Shake well until a clear solution is obtained. After reconstitution, vials will contain 250 mg of active drug per 1.5 mL of solution. The reconstituted solution is stable for 3 days at 70°F or for one week under refrigeration (40° F) For Direct Intravenous Use: Use Sterile Water for Injection, USP or Sodium Chloride Injection, USP.

Add 10 mL to the 1 gram vial and 20 mL to the 2 gram vial. Withdraw the entire contents and administer slowly over a period of approximately10 minutes. For Administration by Intravenous Drip: Reconstitute as directed above (For Direct Intravenous Use) prior to diluting with Intravenous Solution. STABILITY PERIODS FOR OXACILLIN FOR INJECTION, USP Concentration mg/mL Sterile water for Injection 0.9% sodium chloride Injection, USP M/6 Molar Sodium Lactate Solution 5% Dextrose in water 5% Dextrose in 0.45% sodium chloride 10% Invert Sugar Injection, USP Lactated Ringers Solution ROOM TEMPERATURE (25° C) 10 to100 4 Days 4 Days 10 to 30 24 Hrs 24 Hrs 0.5 to 2 6 Hrs 6 Hrs 6 Hrs REFRIGERATION (4° C) 10 to 100 7 Days 7 Days 10 to 30 4 Days 4 Days 4 Days 4 days 4 Days FROZEN (-15° C) 50 to 100 30 Days 250/1.5 mL 30 Days 100 30 Days 10 to 100 30 Days 30 Days 30 Days 30 Days 30 Days Stability studies on oxacillin sodium at concentrations of 0.5 mg/mL and 2 mg/mL in various intravenous solutions listed below indicate the drug will lose less than 10% activity at room temperature (70°F) during a 6-hour period.

IV Solution 5% Dextrose in Normal Saline 10% D-Fructose in Water 10% D-Fructose in Normal Saline Lactated Potassic Saline Injection 10% Invert Sugar in Normal Saline 10% Invert Sugar Plus 0.3% Potassium Chloride in Water Travert 10% Electrolyte #1 Travert 10% Electrolyte #2 Travert 10% Electrolyte #3 Only those solutions listed above should be used for the intravenous infusion of oxacillin sodium. The concentration of the antibiotic should fall within the range specified.

The drug concentration and the rate and volume of the infusion should be adjusted so that the total dose of oxacillin is administered before the drug loses its stability in the solution in use. If another agent is used in conjunction with oxacillin therapy, it should not be physically mixed with oxacillin but should be administered separately.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Do not add supplementary medication to oxacillin for injection, USP.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use Because of incompletely developed renal function in pediatric patients, oxacillin may not be completely excreted, with abnormally high blood levels resulting. Frequent blood levels are advisable in this group with dosage adjustments when necessary. All pediatric patients treated with penicillins should be monitored closely for clinical and laboratory evidence of toxic or adverse effects. Safety and effectiveness in pediatric patients have not been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use Clinical studies of oxacillin for injection did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Oxacillin for Injection contains 57.4 mg (2.5 mEq) per gram Oxacillin. At the usual recommended doses, patients would receive between 57.4 and 343.8 mg (2.5 and 15 mEq) of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to such diseases as congestive heart failure.

Dosage forms

Philippines

  • Powder for injection: 1 g, 500 mg
  • Sterile powder for injection: 500 mg

Registered products in the Philippines

27 products registered with the Food and Drug Administration (FDA) Philippines list Oxacillin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products27
Philippine FDA-registered products for Oxacillin
Package insert
AmboxilOxacillin (as Sodium)
1 g Powder for Injection (IM/IV)USP Type II Clear Glass Vial (Box of 10’s)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
AMB HK Enterprises Inc.
DRP-8190
Aug 18, 2029
AmboxilOxacillin (as Sodium)
500 mg Powder for Injection (IM/IV)USP Type II Clear Glass Vial (Box of 10’s)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
AMB HK Enterprises Inc.
DRP-7913
Aug 18, 2029
BactioxOxacillin (as Sodium)
500 mg Powder for Injection (IM/IV)USP Type I clear and colorless glass vial with grey bromobutyl rubber stopper and aluminum seal with plastic flip-off cap (Box of 1 vial)
Rx
Swiss Parenterals Ltd.India
Endure Medical, Inc.
DR-XY47426
Sep 28, 2028
BactioxOxacillin (as Sodium)
500 mg Powder for Injection (IM/IV)USP Type I clear and colorless glass vial with grey bromobutyl rubber stopper and aluminum seal with plastic flip-off cap (Box of 1 vial)
Rx
Swiss Parenterals Ltd.India
Endure Medical, Inc.
DRP-15942
Sep 28, 2028
BeluxanOxacillin Sodium
500 mg Powder For Injection (I.M./I.V.)7 mL USP Type I Clear Transparent Glass Vial with butyl rubber stopper and aluminum cap (Box of 5's)
Rx
NORTH CHINA PHARMACEUTICAL CO., LTD.China
BELLLUS LIFE SOLUTIONS, INC.Importer: AGLOBAL CARE, INC.
DRP-6179-01
Feb 25, 2029
CilvexOxacillin (As Sodium)
500 mg Powder for Injection (I.M./I.V.)Clear Glass Vial with Magenta Flip Off Seal x 1 (Box of 10's)
Rx
Shandong Xier Kangtai Pharmaceutical Co., Ltd.China
Sannovex Pharmaceutical Distributor
DRP-1956
Feb 25, 2030
FeloxaOxacillin (as Sodium)
500 mg Powder for Injection (IM/IV)USP Type II Clear Glass Vial (Box of 10’s)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
MSF Pharmaceutical Products DistributionImporter: AMB HK Enterprises Inc.
DRP-7913-03
Aug 18, 2029
Goxa IVOxacillin (as sodium)
500 mg Powder for Injection (I.M./I.V.)7 mL-capacity USP Type II clear and colorless glass vial (Box of 1's and 10's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
Go Healthcare Pharmaceutical DistributionImporter: Medinova Pharmaceutical Inc.
DRP-6679-06
May 2, 2028
MinzilOxacillin (As Sodium)
500mg Powder For Injection (IM/IV)USP Type III clear glass vials (Box of 10's)
Rx
Medchem International LimitedIndia
Pharma-Surrey International, Inc.
DRP-522
Nov 17, 2026Past listed date
OcicloxOxacillin (as Sodium)
500 mg Powder for Injection (IM/IV)USP Type III Flint Type Clear and Colorless Glass Vial x 10 mL (Box of 10's)
Rx
Reyoung Pharmaceutical Co. LtdChina
Philgen Pharmaceuticals, Inc.
DRP-3926
Aug 22, 2027
OxacibasOxacillin (as sodium)
1 g Powder for Injection (IV/IM)10 mL USP Type II Clear Glass Vial (Box of 10's)
Rx
Friends Pharma (Pvt.) Ltd.Pakistan
Raquel-Abbas Pharmaceuticals & General Merchandise
DRP-9992
Feb 28, 2029
Oxacisaph-1000Oxacillin (as sodium)
1 g Powder for Injection (IM/IV)USP Type I Clear glass vial with grey bromobutyl rubber stopper and flip-off seal (Box of 1's and 10's)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-16952
Aug 29, 2030
Oxacisaph-500Oxacillin (as sodium)
500 mg Powder for Injection (IM/IV)USP Type I Clear glass vial with grey bromobutyl rubber stopper and flip-off seal (Box of 1's and 10's)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-16951
Aug 29, 2030
Oxamax 500Oxacillin (as sodium)
500 mg Powder for Injection (IM/IV)7 mL Type II Glass Vial Sealed with Gray Butyl Rubber Stopper and Aluminum Cap x 1's (Box of 10's)
Rx
Reyoung PharmaceuticalChina
Dreamax Life Sciences IncorporatedImporter: Dreamax Incorporated
DRP-12578-01
Sep 7, 2027
Oxamed 500Oxacillin (as sodium)
500mg Powder For Injection (IM/IV)7 ml Type II Glass Vial Sealed with Gray Butyl Rubber Stopper and Aluminum Cap xl's (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Importer: Dreamax Incorporated
DRP-12578
Sep 7, 2027
OxanOxacillin (as sodium)
1 g Powder for Injection (IM/IV)10 mL Type I Clear Transparent Glass Vial Sealed with Butyl Rubber Stopper and Aluminum Cap x 1’s (Box of 1’s and 10’s)
Rx
North China Pharmaceutical Co., Ltd.China
Aglobal Care, Inc.
DRP-12577
Sep 7, 2032
OxanOxacillin Sodium
500 mg Powder For Injection (I.M./I.V.)7 mL USP Type I Clear Transparent Glass Vial with butyl rubber stopper and aluminum cap (Box of 5's and 10's)
Rx
North China Pharmaceutical Co., Ltd.China
Aglobal Care, Inc.
DRP-6179
Feb 25, 2029
OxanovaOxacillin (as sodium)
500 mg Powder for Injection (I.M./I.V.)7 mL-capacity USP Type II clear and colorless glass vial (Box of 1's and 10's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc.
DRP-6679-02
May 2, 2028
OxapenOxacillin (as Sodium)
500 mg Powder for Injection (I.M./I.V.)USP Type I Clear and Colorless Glass Vial with Rubber Stopper and Orange Flip-off Seal (Box of 10's)
Rx
Singapore Pharmawealth Lifesciences, Inc.Philippines
—
DRP-709
Mar 4, 2028
OxasOxacillin (as sodium)
500 mg Powder for Injection (I.M./I.V.)7 mL-capacity USP Type II clear and colorless glass vial Box of 1's and 10's
Rx
Reyoung Pharmaceutical Co. Ltd.China
DYNASTY PHARMACEUTICALSImporter: MEDINOVA PHARMACEUTICAL INC.
DRP-6679-01
May 2, 2028
OxavinOxacillin (as sodium)
500 mg Powder for Injection (I.M./I.V,)7 mL-capacity USP Type II clear and colorless glass vial (Box of 1's and 10's))
Rx
Reyoung Pharmaceutical Co. Ltd.China
Medinova Pharmaceutical Inc.
DRP-6679
May 2, 2028
PEOXAOxacillin (as Sodium)
1 g Powder for Injection (I.M./I.V.)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd.
SAHAR INTERNATIONAL TRADING INC.
DR-XY40287
Nov 16, 2026Past listed date
PeoxaOxacillin (as Sodium)
500 mg Powder for Injection (I.M./I.V.)USP Type II Glass Vial (Box of 10's)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd.China
Sahar International Trading Inc.
DR-XY40899
Sep 7, 2028
PeoxaOxacillin (as Sodium)
500 mg Powder for Injection (I.M./I.V.)USP Type II Glass Vial (Box of 10's)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd.China
Sahar International Trading, Inc.
DRP-17865
Sep 7, 2028
SantecilOxacillin (as sodium)
500 mg Powder for Injection (I.M./I.V.)7 mL-capacity USP Type II clear and colorless glass vial (Box of 1's and 10's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
Santerra TradingImporter: Medinova Pharmaceutical Inc.
DRP-6679-05
May 2, 2028
WydoxOxacillin (as sodium)
500 mg Powder for Injection (I.M./I.V.)7 mL-capacity USP Type II clear and colorless glass vial (Box of 1's and 10's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
The Cathay Drug Co., Inc.Importer: Medinova Pharmaceutical Inc.
DRP-6679-04
May 2, 2028
WydoxOxacillin (as Sodium)
500 mg Sterile Powder for Injection (IM/IV)USP Type III Clear Glass Vial with Rubber Stopper and Green Aluminum Seal (Box of 10's)
Rx
YSS Laboratories Co., Inc.Philippines
Trader: The Cathay Drug Co., Inc.
DRP-404
Jun 18, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS Serious and occasionally fatal hypersensitivity (anaphylactic shock with collapse) reactions have occurred in patients receiving penicillin. The incidence of anaphylactic shock in all penicillin-treated patients is between 0.015 and 0.04 percent. Anaphylactic shock resulting in death has occurred in approximately 0.002 percent of the patients treated.

When oxacillin therapy is indicated, it should be initiated only after a comprehensive patient drug and allergy history has been obtained. If an allergic reaction occurs, oxacillin should be discontinued and appropriate therapy instituted. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including oxacillin for injection, USP, and may range in severity from mild diarrhea to fatal colitis.

Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.

CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.

Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Drug interactions

Drug interactions (US label) US FDA label

DRUG INTERACTIONS Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided. Oxacillin blood levels may be increased and prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins. Probenecid decreases the apparent volume of distribution and slows the rate of excretion by competitively inhibiting renal tubular secretion of penicillins.

Oxacillin-probenecid therapy should be limited to those infections where very high serum levels of oxacillin are necessary.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Body as a Whole The reported incidence of allergic reactions to penicillin ranges from 0.7 to 10 percent (see WARNINGS). Sensitization is usually the result of treatment but some individuals have had immediate reactions when first treated. In such cases, it is thought that the patients may have had prior exposure to the drug via trace amounts present in milk and vaccines.

Two types of allergic reactions to penicillins are noted clinically, immediate and delayed. Immediate reactions usually occur within 20 minutes of administration and range in severity from urticaria and pruritus to angioneurotic edema, laryngospasm, bronchospasm, hypotension, vascular collapse and death. Such immediate anaphylactic reactions are very rare (see WARNINGS) and usually occur after parenteral therapy but have occurred in patients receiving oral therapy.

Another type of immediate reaction, an accelerated reaction, may occur between 20 minutes and 48 hours after administration and may include urticaria, pruritus, and fever. Although laryngeal edema, laryngospasm, and hypotension occasionally occur, fatality is uncommon. Delayed allergic reactions to penicillin therapy usually occur after 48 hours and sometimes as late as 2 to 4 weeks after initiation of therapy.

Manifestations of this type of reaction include serum sickness-like symptoms (i.e, fever, malaise, urticaria, myalgia, arthralgia, abdominal pain) and various skin rashes. Nausea, vomiting, diarrhea, stomatitis, black or hairy tongue, and other symptoms of gastrointestinal irritation may occur, especially during oral penicillin therapy.

Nervous System Reactions Neurotoxic reactions similar to those observed with penicillin G may occur with large intravenous doses of oxacillin, especially with patients with renal insufficiency. Urogenital Reaction Renal tubular damage and interstitial nephritis have been associated with the administration of oxacillin. Manifestations of this reaction may include rash, fever, eosinophilia, hematuria, proteinuria, and renal insufficiency.

Nephropathy induced by pencillins does not appear to be dose-related and is generally reversible upon prompt discontinuation of therapy. Gastrointestinal Reaction Pseudomembranous colitis has been reported with the use of oxacillin. The onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment (see WARNINGS).

Metabolic Reactions Agranulocytosis, neutropenia, and bone marrow depression have been associated with the use of oxacillin. Hepatotoxicity, characterized by fever, nausea, and vomiting associated with abnormal liver function tests, mainly elevated SGOT levels, has been associated with the use of oxacillin. To report SUSPECTED ADVERSE REACTIONS, contact Onesource at 1-888-217-8103 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Teratogenic Effects Pregnancy Category B Reproduction studies performed in the mouse, rat, and rabbit have revealed no evidence of impaired fertility or harm to the fetus due to the penicillinase-resistant penicillins. Human experience with the penicillins during pregnancy has not shown any positive evidence of adverse effects on the fetus.

There are, however, no adequate or well-controlled studies in pregnant women showing conclusively that harmful effects of these drugs on the fetus can be excluded. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers Penicillins are excreted in human milk. Caution should be exercised when penicillins are administered to a nursing woman.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Slow I.V administration of 500 mg gives a peak serum level of 43 mcg/mL after 5 minutes with a half-life of 20 to 30 minutes.

Oxacillin Sodium is rapidly excreted as unchanged drug in the urine by glomerular filtration and active tubular secretion.

The elimination half-life for oxacillin is about 0.5 hours.

Nonrenal elimination includes hepatic inactivation and excretion in bile.

Slow IV dosing with 500 mg gives a 5 minute peak of 43 mcg/mL with a half-life of 20 to 30 minutes.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Intravenous administration provides peak serum levels approximately 5 minutes after the injection is completed. Slow I.V administration of 500 mg gives a peak serum level of 43 mcg/mL after 5 minutes with a half-life of 20 to 30 minutes. Oxacillin sodium, with normal doses, has insignificant concentrations in the cerebrospinal and ascitic fluids.

It is found in therapeutic concentrations in the pleural, bile, and amniotic fluids. Oxacillin Sodium is rapidly excreted as unchanged drug in the urine by glomerular filtration and active tubular secretion. The elimination half-life for oxacillin is about 0.5 hours. Nonrenal elimination includes hepatic inactivation and excretion in bile.

Oxacillin sodium binds to serum protein, mainly albumin. The degree of protein binding reported varies with the method of study and the investigator, but generally has been found to be 94.2 ± 2.1%. Probenecid blocks the renal tubular secretion of penicillins. Therefore, the concurrent administration of probenecid prolongs the elimination of oxacillin and, consequently, increases the serum concentration.

Intramuscular injections give peak serum levels 30 minutes after injection. A 250 mg dose gives a level of 5.3 mcg/mL while a 500 mg dose peaks at 10.9 mcg/mL. Intravenous injection gives a peak about 5 minutes after the injection is completed. Slow IV dosing with 500 mg gives a 5 minute peak of 43 mcg/mL with a half-life of 20 to 30 minutes.

MICROBIOLOGY Mode of Action Penicillinase-resistant penicillins exert a bactericidal action against penicillin susceptible microorganisms during the state of active multiplication. All penicillins inhibit the biosynthesis of the bacterial cell wall. Mechanism of Resistance Resistance to penicillins may be mediated by destruction of the beta-lactam ring by a beta-lactamase, altered affinity of penicillin for target, or decreased penetration of the antibiotic to reach the target site.

Cross Resistance Resistance to oxacillin (or cefoxitin) implies resistance to all other beta-lactam agents, except newer agents with activity against methicillin-resistant Staphylococcus aureus. Susceptibility Test Methods When available, the clinical microbiology laboratory should provide of in vitro susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens.

These reports should aid the physician in selecting the most effective antibacterial drug for treatment. Dilution techniques Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method 1,2 (broth and/or agar).

The MIC values should be interpreted according to the criteria in Table 1. Diffusion techniques Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized method. 2,3 .It has been determined that the most accurate method to test the susceptibility of microorganisms to penicillinase resistant penicillins, including oxacillin, by disk diffusion is achieved using disks impregnated with 30 mcg cefoxitin.

Interpretation involves correlation of the diameter obtained with the cefoxitin disk test with the MIC for oxacillin 2. Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30 microgram cefoxitin disk should be interpreted according to the following criteria in Table 1. Table 1: Susceptibility Test Interpretive Criteria for Oxacillin Pathogen Antimicrobial Disk Disk Diffusion Zone Diameter Minimum Inhibitory Agent Content (mm) a Concentrations (mcg/mL) S I R S I R Staphylococcus aureus and S. lugdenensis C Oxacillin - - - - ≤ 2 (oxacillin) - ≥ 4 (oxacillin) 30 mcg cefoxitin b ≥ 22 - ≤ 21 ≤ 4 (cefoxitin) - ≥ 8 (cefoxitin) Coagulase- negative Staphylococci except S.lugdenensis Oxacillin d - - - - ≤ 0.25 - ≥ 0.5 30 mcg cefoxitin b ≥25 - ≤24 - - - S=susceptible, I=intermediate, R-resistant a In most staphylococcal isolates, oxacillin resistance is mediated by mecA, encoding the penicillin binding protein 2a (PBP2a, also called PBP2’).

Isolates that test positive for mecA or PBP2a should be reported as oxacillin resistant.” 2b Cefoxitin is used as a surrogate for oxacillin; report oxacillin susceptible or resistant based on the cefoxitin result. 2c If both cefoxitin and oxacillin are tested against S. aureus or S. lugdenensis, and either result is resistant, the organism should be reported as oxacillin resistant. 2d Oxacillin MIC interpretive criteria may overcall resistance for some coagulase-negative staphylococci (CoNS), because some non- S. epidermidis strains for which the oxacillin MICs are 0.5 to 2 mcg/ml lack mecA. For serious infections with CoNS other than S. epidermidis, testing for mecA or for PBP 2a or with cefoxitin disk diffusion A report of “Susceptible” indicates that the antimicrobial is likely to inhibit the growth of the pathogen if the antimicrobial compound reaches the concentrations at the infection site necessary to inhibit growth of the pathogen.

A report of “Intermediate” indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated.

This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the infection site; other therapy should be selected.

Quality Control Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test. 1,2,3 Standard oxacillin powder should provide the following range of MIC values 1 noted in Table 2. For the diffusion technique using the 30 mcg cefoxitin disk, the criteria in Table 2 should be achieved.

Table 2. Acceptable Quality Control Ranges for Susceptibility Testing* Quality Control Organism Minimum Inhibitory Concentration (mcg/mL) Disk Diffusion Zone Diameters (mm) Enterococcus faecalis ATCC ® 29212 8-32 - Staphylococcus aureus ATCC ® 25923 - 18-24 Staphylococcus aureus ATCC ® 29213 0.12 - 0.5 - Streptococcus pneumonia ATCC ® 49619 a - ≤12 b ATCC=American Type Culture Collection a Despite the lack of reliable disk diffusion interpretive criteria for S.pneumoniae with certain beta-lactams, Streptococcus pneumonia ATCC ® 49619 is the strain designated for QC of all disk diffusion tests with Streptococcus spp. b Deterioration of oxacillin disk content is best assessed with QC organisms S.aureus ATCC ® 25923, with an acceptable zone diameter for 18-24.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Oxacillin 500 mg Vial₱12.00–₱130.00Reference ₱17.88per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Oxacillin (as sodium salt)
PNF listingInj.: 250 mg and 500 mg vial (IM, IV)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. oxacillin · Onesource Specialty Pharma Limited [US FDA-approved label, version 1, December 31, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4972ec74-1d9a-de9b-e063-6394a90af786
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .